Yakult for stronger muscles? study tests probiotic against sarcopenia

NCT ID NCT04985877

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a fermented milk drink containing Lactobacillus casei strain Shirota (sold as Yakult) could improve gut health and slow muscle loss in 132 elderly Taiwanese adults with sarcopenia. Participants drank two bottles daily for 12 weeks. Researchers measured changes in gut bacteria, muscle mass, and strength. The goal was to see if the probiotic could reduce inflammation and support muscle function through the gut-muscle axis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
fermented milk containing Lactobacillus casei strain Shirota (probiotic)
What this could lead to
If it works, this could point toward a simple dietary supplement to help slow muscle loss and improve strength in older adults with sarcopenia.
What could go wrong
This is a small, completed study (132 people) with no blinding or placebo control, so results may be due to chance or other factors. The benefits seen may not apply to other populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

132 people

The number who actually took part.

Started

Mar 2021

Finished

Feb 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Sarcopenia without treatment Inclusion Criteria: 1. Age between 65 and 85 years 2. No use of hormonal replacement therapy (women) 3. No hospital admissions within the last 3 months 4. Sarcopenia criteria: (1) Muscle mass: measured by using InbodyS10 and standardized by height, shown by skeletal muscle index \[SMI=appendicular muscle mass (kg)/height (m2)\]. Low muscle mass was defined as: * Men: SMI \<7.0 kg/m2 * Women: SMI \<5.4 kg/m2 (2) Handgrip strength: measured by electronic hand grip dynamometer. Low handgrip strength was defined as: * Men: \<28 kg * Women: \<18 kg (3) Limb strength: measured by Time for 5 times for chair stand method. Low limb strength was defined as: * Time for 5 times for chair stand: ≧12s Sarcopenia was defined by (1), (2) or (3) Sarcopenia plus Lactobacillus casei strain Shirota (LcS) Inclusion Criteria: 1. Age between 65 and 85 years 2. No use of hormonal replacement therapy (women) 3. No hospital admissions within the last 3 months 4. Sarcopenia criteria: (1) Muscle mass: measured by using InbodyS10 and standardized by height, shown by skeletal muscle index \[SMI=appendicular muscle mass (kg)/height (m2)\]. Low muscle mass was defined as: * Men: SMI \<7.0 kg/m2 * Women: SMI \<5.4 kg/m2 (2) Handgrip strength: measured by electronic hand grip dynamometer. Low handgrip strength was defined as: * Men: \<28 kg * Women: \<18 kg (3) Limb strength: measured by Time for 5 times for chair stand method. Low limb strength was defined as: * Time for 5 times for chair stand: ≧12s Sarcopenia was defined by (1), (2) or (3) Exclusion Criteria of Three groups: 1. Active cancer: currently receiving cancer treatment or have received cancer treatment within the last 3 months 2. Weight change ≥ 5% or weight change ≥ 5 kg within the past 3 months 3. BMI \> 35 kg/m2 4. Disease requiring chronic use of prescription corticosteroids 5. History of ischemic or hemorrhage stroke 6. Unstable or uncontrollable hypertension (\>180/110 mmHg) 7. Doing hemodialysis or peritoneal dialysis within the last 3 months 8. Participation in a structured physical exercise training program within the past 2 year; previous use of creatinine supplementation; use of drugs that can affect bone metabolism (e.g., glucocorticoids, bisphosphonates, vitamin D or calcium). 9. Antibiotics were used in the past 3 months. 10. Products of probiotic were used in the past 2 weeks. 11. Living abroad for one month in the past 3 months 12. Hyperthyroidism without medication therapy 13. Allergic to milk

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aging are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Inflammation inflammatory disease Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Taipei Medical University

    Taipei, 110, Taiwan

  • Taipei Medical University Hospital

    Taipei, 110, Taiwan

  • Wanfang Hospital

    Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.